Related Experiment Video
Updated: Aug 29, 2025

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
Published on: July 16, 2016
Advances in insulin therapy from discovery to β-cell replacement
Teruaki Sakurai1,2, Sodai Kubota1,2,3, Takehiro Kato1,2
1Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine, Gifu, Japan.
Insulin therapy has evolved from animal-sourced insulin to recombinant human insulin. Future advancements may include beta-cell replacement therapy for diabetes treatment.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Biotechnology
Background:
- The advent of insulin therapy in the 1920s, utilizing animal-sourced insulin, marked a significant breakthrough in managing diabetes mellitus.
- Subsequent scientific progress, including the cloning of human insulin complementary DNA (cDNA), facilitated the creation of recombinant human insulin.
Purpose of the Study:
- To provide a historical overview of insulin therapy evolution for diabetes.
- To highlight key advancements in insulin production and treatment modalities.
- To explore the potential future of diabetes management through beta-cell replacement therapy.
Main Methods:
- Review of historical scientific literature on insulin therapy.
- Analysis of biotechnological advancements in insulin production.
- Prospective evaluation of emerging therapeutic strategies for diabetes.
Main Results:
- Early insulin therapy, derived from porcine and bovine sources, dramatically improved diabetes outcomes.
- Recombinant DNA technology enabled the production of human insulin with enhanced characteristics.
- Beta-cell replacement therapy is emerging as a promising future direction for diabetes treatment.
Conclusions:
- Insulin therapy has undergone substantial evolution, from animal extracts to bioengineered human insulin.
- Continued innovation in biotechnology and regenerative medicine is poised to transform diabetes care.
- Beta-cell replacement therapy represents a potential paradigm shift in managing diabetes in the future.
Related Concept Videos
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin Secretory Vesicles

